JPMorgan Chase & Co. (JPM) Analysts Raise Price Target on Insmed (INSMD) to $25.00

 Source: ABMN Staff   |   Publish date: Mon, 13 Jun 2011, 01:26 PM   |    >> Read article in News website

Equities research analysts at JPMorgan Chase & Co. (NYSE: JPM) boosted their price target on shares of Insmed (NASDAQ: INSMD) to $25.00 in a research note to investors on Friday.

Insmed Incorporated (Insmed) is a biopharmaceutical company specializing in recombinant protein drug development. Until 2009, the Company was engaged in pursuing a dual path strategy involving entry into the follow-on biologics (FOB) arena (also known as biosimilars, biogenerics and biologics) and advancing its protein platform, centered on its IPLEX product, into markets with unmet needs. IPLEX is in various stages of development for a number of serious medical conditions, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, and Retinopathy of Prematurity (ROP). On March 31, 2009, the Company completed the sale of its FOB platform to Merck & Co., Inc. (Merck).

Share this

  Be the first to like this.
buy4long I do not believe that JPM wrote any investment opinion abount Insmed. No one on any website and in multiple forums has been able to produce any content from this research note.

This is either an honest error or shenanigans.
14/06/2011 22:51
Trader Hub I believe this is accurate. It is discussed in Yahoo group as well:
15/06/2011 21:55


4111  2766  850  642 

Top 10 Active Counters
 EEM 33.94-0.76 
 GDX 13.45-0.26 
 SPY 209.56+0.24 
 FREE 0.04+0.01 
 GE 30.360.00 
 SUNE 3.36+0.11 
 GBSN 0.13+0.022 
 UGAZ 2.58-0.24 
 BAC 17.48+0.04 
 FXI 36.93-1.04 
Partners & Brokers